Sphere Fluidics

Founded in 2010, Sphere Fluidics is an established Life Sciences company, originally spun out from the University of Cambridge. They have extended their expertise and are developing a technology platform that enables discovery in a range of growing markets through single cell analysis. Their systems make the development of new biopharmaceuticals faster and more cost-effective, improve monoclonal antibody screening, cell line development, and overall research efficiency in a number of other applications including synthetic biology, single cell diagnostics, prognostics and single cell genome editing.

More information at https://spherefluidics.com.